Interleukin 6‐blockade treatment for severe COVID‐19 in two patients with multiple myeloma
Open Access
- 5 May 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 190 (1) , E9-E11
Abstract
Coronavirus disease 2019 (COVID‐19) presents with a broad clinical spectrum, varying from asymptomatic infection to severe pneumonitis, leading to acute respiratory distress syndrome (ARDS) and death(Guan, et al 2020). Accumulating evidence suggests that in severe COVID‐19, an acute hyperinflammatory syndrome characterised by fever, hypoxia and increased serum inflammatory markers, occurring 5‐10 days from the first symptoms, is the major driver of morbidity and death(Zhou, et al 2020b). Hyperinflammation is not specific to COVID‐19. Similar syndromes were previously described in respiratory disease associated with other coronaviruses, including the severe acute respiratory syndrome–coronavirus (SARS‐CoV) in 2003 and Middle East respiratory syndrome–coronavirus (MERS‐CoV) in 2012(Castilletti, et al 2005, Tseng, et al 2005).Keywords
This publication has 14 references indexed in Scilit:
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patientsNational Science Review, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Targeting Interleukin-6 Signaling in ClinicImmunity, 2019
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018
- Immunotherapeutic Implications of Il-6 Blockade for Cytokine StormImmunotherapy, 2016
- Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working PartyJournal of Clinical Oncology, 2005
- Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replicationVirology, 2005
- Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive InfectionThe Journal of Immunology, 2005